Genmab A/S
GMAB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434265
No open-market purchases or sales by Genmab A/S insiders were filed in the last 90 days; 291 institutions reported holding it in 13F filings for Q2 2026, worth $2.81B in total; no superinvestor holds it.
Other share classesGNMSF
Q3 2023 vs. Q2 2023
How the institutions holding Genmab A/S changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 214 | 234 | +20 |
| Shares | 41.7M | 47.5M | +5.75M (+13.8%) |
| Value | $1.59B | $1.67B | +$89.5M (+5.6%) |
New holders (41)
Institutions that held Genmab A/S at the end of Q3 2023 but not at the end of Q2 2023.
Sold out (21)
Institutions that held Genmab A/S at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Two Sigma Investments, LP | 134,913 | $5.13M |
| Voloridge Investment Management, LLC | 61,055 | $2.32M |
| Clear Street Markets LLC | 5,551 | $2.10M |
| Arlington Capital Management, Inc. | 36,489 | $1.39M |
| Susquehanna Fundamental Investments, LLC | 19,371 | $736.3K |
| Ensign Peak Advisors, Inc | 18,200 | $691.8K |
| Campbell & CO Investment Adviser LLC | 15,804 | $600.7K |
| Engineers Gate Manager LP | 11,617 | $441.6K |
| Dynamic Technology Lab Private Ltd | 8,120 | $309.0K |
| Vident Investment Advisory, LLC | 7,842 | $298.0K |
| Susquehanna International Group, LLP | 6,147 | $233.6K |
| Pacer Advisors, Inc. | 5,810 | $220.8K |
| Ellevest, Inc. | 5,609 | $213.2K |
| TD Ameritrade Investment Management, LLC | 2,254 | $86.0K |
| Deutsche Bank AG | 1,951 | $74.2K |
| Bollard Group LLC | 427 | $16.0K |
| Bessemer Group Inc | 250 | $10.0K |
| Simplex Trading, LLC | 121 | $4.00K |
| Impact Partnership Wealth, LLC | 46 | $1.75K |
| Fairfield, Bush & Co. | 30 | $1.14K |
| Motco | 13 | $494 |